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Abstract
Background: The variability of maternal serum biochemical markers for Down syndrome, free b-hCG and PAPP-A
can have a different impact on false-positive rates between the 10+0 and 13+6 week of gestation. The study
population comprised 2883 unaffected, singleton, spontaneously conceived pregnancies in Croatian women, who
delivered apparently healthy child at term. Women were separated in 4 groups, dependently on the gestational
week when the analyses of biochemical markers were performed. The concentrations of free b-hCG and PAPP-A in
maternal serum were determined by solid-phase, enzyme-labeled chemiluminiscent immunometric assay (Siemens
Immulite). Concentrations were converted to MoMs, according to centre-specific weighted regression median
curves for both markers in unaffected pregnancies. The individual risks for trisomies 21, 18 and 13 were computed
by Prisca 4.0 software.
Findings: There were no significant differences between the sub-groups, regarding maternal age, maternal weight
and the proportion of smokers. The difference in log10 MoM free b-hCG values, between the 11
th and 12
th
gestational week, was significant (p = 0.002). The difference in log10 MoM PAPP-A values between the 11
th and
12
th, and between 12
th and 13
th week of gestation was significant (p = 0.006 and p = 0.003, respectively). False-
positive rates of biochemical risk for trisomies were 16.1% before the 11
th week, 12.8% in week 12
th, 11.9% in week
13
th and 9.9% after week 13
th. The differences were not statistically significant.
Conclusions: Biochemical markers (log10 MoMs) showed gestation related variations in the first-trimester
unaffected pregnancies, although the variations could not be attributed either to the inaccuracy of analytical
procedures or to the inappropriately settled curves of median values for the first-trimester biochemical markers.
Findings
The first-trimester screening for trisomies 21, 18
and 13, combining maternal age, fetal nuchal translu-
cency thickness (NT), maternal serum free b-human
chorionic gonadotropin (free b-hCG) and pregnancy
associated plasma protein-A (PAPP-A) has revealed a
highly potential possibility of an early detection of fetal
aneuploidies [1-5].
Various co-variables influence the specificity and sen-
sitivity of the first-trimester biochemical markers have
been studied [6]. Corrections of the calculated gesta-
tional MoM values (Multiples of the Median) have been
proposed for maternal weight, cigarette consumption,
ethnicity and twin-pregnancy [7-10]. Fetal gender,
maternal insulin-dependent diabetes mellitus, parity/
gravidity and procedures in assisted reproduction show
certain, but insignificant influence on the screening
performance [11-15].
Several studies have focused on the optimal timing for
analysis of biochemical markers, predominantly
concerning their sensitivity for fetal trisomies [16,17].
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12 weeks’ gestation, being significantly reduced towards
the 13
th week [18]. Clinical sensitivity of free b-hCG
becomes evident from the 10
th week, ongoing towards
the second trimester of pregnancy [19].
To our knowledge, there has been a lack of publica-
tions, which presume the precision of the applied analy-
tical methods to the physiological variations of maternal
serum markers across the first trimester. This retrospec-
tive study in Croatian women with unaffected pregnan-
cies has the aim to: (a) assess the specificity of free
b-hCG and PAPP-A across the first-trimester in terms
of the false-positive rate (FPR) for trisomy 21 in particu-
lar weeks and (b), to examine the analytical accuracy of
the methods applied for the measurement of biochem-
ical markers.
Methods
In Croatia, combined screening for fetal trisomies has
been performed from February 2006. Our Laboratory
has been the only centre, which has conducted the ana-
lyses for biochemical markers according to the recom-
mendations of the Fetal Medicine Foundation (www.
fetalmedicine.com). Also, we have been included in
external proficiency testing program (UK NEQAS First
Trimester Down Syndrome Screening) since August
2006.
Out of total 3118 pregnant women who underwent
the combined screening for chromosomal abnormalities
till May 2008, a cohort of 2883 subjects was retrospec-
tively recruited from the entire population. The selec-
tion criteria included non-diabetic, Caucasian women,
with singleton, spontaneously conceived pregnancy, who
delivered apparently healthy child at term. Pregnancies
with abnormal fetal karyotype and those spontaneously
aborted were excluded, on the basis of the data supple-
mented from health-care providers and delivery records
in maternity units, respectively.
A l lp r e g n a n tw o m e nh a da nu l t r a s o u n de x a m i n a t i o n
between weeks 10+0 and 13+6, which included the
crown-rump (CRL) measurement for pregnancy dating
and the correspondent NT value, respectively. The
obstetrician filled the form with all the clinical data rele-
vant for the pregnancy and the mother. The Hospital
Ethics Committee approved the accessibility of the first-
trimester screening to all pregnant women (E.C. No.19-
1/2006). Each woman signed informed consent for the
combined screening.
The concentrations of maternal serum free b-hCG and
PAPP-A were determined by solid-phase, enzyme-
labelled chemiluminiscent immunometric assay
(Siemens Medical Solution Diagnostics). Assays were
performed on automated platform Immulite 1000. Med-
ian levels of free b-hCG and PAPP-A in unaffected
pregnancies were calculated from weighted regression of
observed medians for each gestational day. For that pur-
pose, pregnancies achieved by the methods of assisted
conception, twins, diabetic pregnant women and preg-
nancies with confirmed fetal aneuploidies were excluded
from the database. The data fitted the exponential equa-
tion well; observed medians were close to those pre-
dicted from the model. Regressed medians were used to
generate multiples of the median (MoM) for each case.
MoM values of markers were corrected for maternal
weight and smoking cigarettes and individual risks for
trisomies 21, 18 and 13 for each of the pregnant women
were calculated using the Prisca 4.0 software (Typolog,
Germany).
To assess the accuracy of the analytical procedures,
specimens of Siemens control modules LPCCM and
LFBCM were run in a day-routine (three-level control
containing free b-hCG in the lyophilized serum prepara-
tion and two-level control for PAPP-A in non-human
serum matrix, respectively). To examine the within-run
precision, 15 replicates of each control were analyzed
sequentially. To evaluate the between-day precision, an
aliquot of the same lot of control specimen was run
along with daily routine measurements. In addition, an
aliquot of pooled pregnant women sera was run with
daily batch of unknown samples.
The impact of variability of biochemical marker MoM
values on the risk for trisomy 21 was assessed using the
appropriate 15 paired concentrations of free b-hCG and
PAPP-A in controls and in human pooled sera as well,
in combination with a fixed clinical pattern (CRL, NT,
maternal age and maternal weight) and the relevant
risks were computed.
Statistical analyses were performed using MedCalc®
software and descriptive statistics using Excel 7.0,
respectively. The normality of distributions of log10
MoMs of biochemical markers was ascertained using
Kolgomorov-Smirnov test. Proportions of smokers and
FPR in particular weeks were determined by c
2 test.
The differences in maternal age and maternal weight,
between particular weeks, were assessed by one-way
ANOVA. The level of p < 0.05 was considered statisti-
cally significant.
Results
The data concerning within-run and between-day analy-
tical precision for the biochemical markers are presented
in table 1. Table 2 shows the within- and between-day
variations of biochemical and combined risk, in the
three levels of risk values. The within-day coefficient of
variation (CV) varied between 9.45-11.72% for biochem-
istry only and between 10.45-12.98% for combined risk,
respectively. The between-day variations of the bio-
chemical risk were between 10.39-12.47%, and of the
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Page 2 of 7Table 1 Within-run and between-day precision of measurement of free b-hCG and PAPP-A, using Siemens Control
Modules and human pooled sera on automated platform Immulite 1000
Free b-hCG (ng/ml) PAPP-A (mIU/ml)
Sample Control Module LFBCM Human serum Control Module LPCCM Human serum
Control 1 Control 2 Control 3 Control 1 Control 2
Target 5.1 23.8 74.2 0.40 1.96
2SD Range (4.2-6.4) (19.8-27.8) (63.6-90.8) (0.32-0.48) (1.70-2.22)
Within-run
Mean 4.84 24.1 72.8 66.6 0.41 1.94 2.58
SD 0.15 1.12 3.50 2.40 0.01 0.06 0.17
CV* (%) 3.09 4.65 4.81 3.60 2.44 3.09 6.59
Between-run
Mean 4.75 22.66 71.66 61.7 0.38 1.94 2.39
SD 0.31 1.70 5.25 4.13 0.02 0.11 0.21
CV* (%) 6.52 7.50 7.32 6.69 5.26 5.67 8.79
CV* - coefficient of variation
Table 2 Impact of within-day and between day variations on assessment of biochemical and combined risk for Down
syndrome
Free b-hCG
MoM
PAPP-A
MoM
Biochemical risk
(1 in)
Combined risk
(1 in)
Within-day variations of calculated risk High risk *
Mean ± SD 1.87 ± 0.08 0,29 ± 0,01 52.6 ± 6.2 154.4 ± 16.1
CV† (%) 4.27 3.45 11.72 10.45
Medium risk **
Mean ± SD 0.59 ± 0,03 0,29 ± 0,01 732.6 ± 76.0 699.9 ± 77.2
CV† (%) 5.08 3.45 10.37 11.03
Low risk ***
Mean ± SD 1.87 ± 0.08 1.26 ± 0.05 3060.8 ± 323.5 2527.7 ± 328.3
CV† (%) 4.27 3.97 10.57 12.98
Human serum
Mean ± SD 1.47 ± 0.07 1.79 ± 0.06 8668.2 ± 819.4 7313.9 ± 900.9
CV† (%) 4.76 3.35 9.45 12.32
Between-day variations of calculated risk High risk *
Mean ± SD 1.70 ± 0.09 0.27 ± 0.01 45.39 ± 5.5 145.6 ± 18.2
CV† (%) 5.26 3.43 12.12 12.50
Medium risk* *
Mean ± SD 0.59 ± 0.03 0.27 ± 0.01 661.4 ± 68.7 646.1 ± 68.58
CV† (%) 4.3 3.43 10.39 11.54
Low risk ***
Mean ± SD 1.70 ± 0.09 1.26 ± 0.05 2442.6 ± 304.6 1993.3 ± 219.7
CV† (%) 5.26 4.28 12.47 11.02
Human serum
Mean ± SD 1.36 ± 0.08 1.76 ± 0.09 7446.5 ± 796.8 6146.4 ± 785.4
CV† (%) 6.17 5.20 10.70 12.77
*Biochemistry: Control 3 (free b-hCG) + Control 1 (PAPP-A); Patient: 25 years, non-smoker, 67 kg, CRL = 45 mm, NT = 1.5 mm
**Biochemistry: Control 2 (free b-hCG) + Control 1 (PAPP-A); Patient: 25 years, non-smoker, 67 kg, CRL = 45 mm, NT = 1.8 mm
***Biochemistry: Control 3 (free b-hCG) + Control 2 (PAPP-A); Patient: 25 years, non-smoker, 67 kg, CRL = 45 mm, NT = 1.8 mm
CV† - coefficient of variation
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Page 3 of 7combined risk between 11.02-12.77%, depending on the
particular risk level.
To investigate a possible gestation-dependent biological
variability of biochemical markers, the pregnant women
were classified in 4 groups, according to gestational age
at blood sampling. There were no significant differences
between the sub-groups, regarding maternal age, mater-
nal weight and the proportion of smokers (table 3).
The distribution of maternal serum free b-hCG and
PAPP-A MoM values, according to gestational age, are
presented in table 4. Median MoMs of both markers
were close to 1.0 in all of four weeks of gestation. For
the both analytes and in all of the weeks, log10 MoM
values fitted the Gaussian distribution, with overall stan-
dard deviation for free b-hCG of 0.2600, and 0.2307 for
PAPP-A, respectively.
Table 5 presents the results of assessment of variability
for log10 MoM values of free b-hCG and PAPP-A
between particular weeks. Using ANOVA, we showed sta-
tistically significant difference in log10 MoM values of free
b-hCG between the 11
th and 12
th gestational week
(p = 0.002). In addition, significant differences were scer-
tained for log10 MoM PAPP-A between the 11
th and 12
th,
as well as between 12
th and 13
th week of gestation
(p = 0.006 and p = 0.003, respectively). Post-hoc Student-
Newman-Keuls test was used to assess the significance of
the difference between subgroups.
In table 6, we compared the FPR of biochemical risk
for trisomies in particular weeks of first-trimester gesta-
tion, considering the cut-off values 1:300 for trisomy
21 and 1:100 for trisomies 18 and 13, respectively. The
proportion of pregnant women, classified at increased
biochemical risk, was 16.1% in the group before the 11
th
week, 12.8% between weeks 11 and 11+6, 11.9% between
weeks 12 and 12+6, and 9.9% between weeks 13 and
13+6, respectively. The differences in proportions were
not statistically significant, neither for the risks concern-
ing trisomy 21 nor for trisomies 18/13.
Discussion
Introducing the first-trimester screening for fetal trisomies
in Croatian pregnant women has been the opportunity for
the improvement of prenatal care in our country [20,21].
Previous studies have reported considerable variations in
analytical procedures and precision of analyte measure-
ment from different laboratories providing biochemical
analyses [22]. That refers not only to the accuracy of mea-
sured concentrations of free b-hCG and PAPP-A, but also
to converting them to the appropriate MoM values, and as
the consequence, estimating the computed risks for fetal
aneuploidies. In our country we have quite uniform popu-
lation of women, concerning their demographic, social
and ethnic background [20]. In that way, we have the
opportunity to create the stable population median values
Table 3 Distribution of pregnancies through gestation according to demographic characteristics
Group Week of gestation Number Maternal age
(years)*
Mean ± SD
Maternal weight
(kg) **
Mean ± SD
Smokers ***
N (%)
1 10 to 10+6/7 96 31.7 ± 4.5 66.9 ± 12.8 10 (10.4%)
2 11 to 11+6/7 853 31.5 ± 4.6 66.4 ± 11.2 91 (10.7%)
3 12 to 12+6/7 1326 31.4 ± 4.4 65.4 ± 10.6 153 (11.5%)
4 13 to 13+6/7 608 31.4 ± 4.4 65.6 ± 10.4 61 (10.0%)
Total 2883 31.5 ± 4.5 66.1 ± 11.3 315 (10.9%)
* p = 0.834 (one-way analysis of variance)
** p = 0.124 (one-way analysis of variance)
*** p = 0.779 (c
2 =1.093)
Table 4 Distribution of maternal serum free b-hCG and PAPP-A MoM values, according to gestational age
Free b-hCG MoM PAPP-A MoM
Group Week of gestation Median Mean
log10
SD
log10
CV*
(%)
Median Mean
log10
SD
log10
CV*
(%)
1 10 to 10+6/7 1.04 -0.0655 0.2494 0.04 0.99 0.0043 0.2398 0.55
2 11 to 11+6/7 0.98 0.0294 0.2651 0.09 0.98 -0.0177 0.2204 0.12
3 12 to 12+6/7 0.99 0.0334 0.2619 0.08 0.99 0.0170 0.2335 0.14
4 13 to 13+6/7 1.03 0.0294 0.2637 0.09 1.02 0.0453 0.2290 0.05
Total 1.00 0.0067 0.2600 - 0.98 0.0122 0.2307 -
Gaussian distribution was confirmed by Kolgomorov-Smirnov test for normality
MoM - Multiples of the Median
CV* - coefficient of variation
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biochemistry from a single Laboratory. The MoM values
for both analytes were close to 1.00 in each of the weeks,
suggesting that the applied medians have been appropri-
ate. We also have proved that the distribution of log10
MoM values of both markers fits a Gaussian curve, with
SDs comparable with the results of much greater series in
the literature [1-5]. Our results undoubtedly demonstrated
the precision of the measurement of biochemical markers.
Coefficients of intra- and inter-assay variations for both
markers were exactly as proposed by the manufacturer.
Concerning the fact that all analytical procedures were
performed on automatic Immulite 1000 system, the data
suggest more accurate and precise measurement perfor-
mance than Spencer demonstrated when he had evaluated
Immulite 2000 versus Kryptor platform [23]. He estab-
lished a significant positive bias for PAPP-A (20.65%)
against the ALTM of UK NEQAS for first-trimester
screening. As of our experience, we disagree with this
statement, since our Laboratory participates with the
Immulite technology in the same program. The proceed-
ings of NEQAS have demonstrated that our BIAS in
PAPP-A concentrations, against ALTM, has been -1.8%
(VAR 4.8%), while BIAS for MoM values have been
-12.6% (VAR 9.4%). On the other side, BIAS for free
b-hCG has been -1.7% (VAR -4.1%) and for MoM values
+1.4% (VAR +4.1%), respectively. Most probably, some
considerable analytical improvements may have occurred
for free b-hCG and PAPP-A immunoassays on Immulite
platforms since the year 2005, when Spencer published his
study. Nonetheless, we can confirm that we have
succeeded in keeping the high technical standards for
biochemical marker analyses [24]. In line with Spencer’s
recommendations, the assessment of calculated risk varia-
bility is an obligatory and useful tool in quality control
[25]. We have shown that within-day and between-run
CVs of calculated risks were, in rough, between 10-13%.
This is to some extent higher than 8%, which is the opti-
mal CV for target risk, but we need to continue with this
monitoring for a longer period to have the more represen-
tative experience. On the other hand, proper risk classifi-
cation of pregnant women can be influenced not only by
biochemical markers, but even more, by the imprecise
measurement of ultrasonic markers, which is outside the
scope of this study.
From the point of clinical interest, the most important
is the discriminatory power of both biochemical markers
across the first-trimester. The impact of variability of
free b-hCG and PAPP-A on their clinical sensitivity was
clearly demonstrated in studies of Spencer and his co-
workers [26,27].
To examine biological variations in normal pregnan-
cies, we studied the variability of marker concentrations
and their MoM values across the first trimester. The
uniformity of sub-groups in particular weeks was proved
by means of ANOVA and c
2 test. The compliance of
log10 MoM values with normal distributions, and insig-
nificant changes of SDs of both markers in particular
weeks did not show any significant oscillations of the
values of free b-hCG and PAPP-A. When we compared
log-transformed MoM values between weeks by
ANOVA, statistically significant differences were found
for free b-hCG MoM values between the first two
weeks. On the other side, significant differences
for PAPP-A MoM values were established between
sub-groups in later weeks of the first trimester.
Table 5 Variability of log10 MoM values of free b-hCG and PAPP-A between particular weeks
Free b-hCG PAPP-A
Between-weeks’ difference Sample
size
F-ratio Significance
level
F-ratio Significance
level
Group 1 vs. Group 2 (10+0 to 11+6) 949 9.221 p = 0.002* 0.191 p = 0.294
Group 2 vs. Group 3 (11+0 to 12+6) 2179 0.0372 p = 0.847 7.445 p = 0.006*
Group 3 vs. Group 4 (12+0 to 13+6) 1934 0.947 p = 0.331 8.942 p = 0.003*
All 2883 3.516 p = 0.015* 8.696 p < 0.001*
* Statistically significant (one-way analysis of variance)
Table 6 Comparison of the false positive rates (FPR) in calculated biochemical risk in particular weeks
Group Week of gestation Risk for trisomy 21
(Cut-off ≤1:300)
N/Total (%)
Risk for trisomy 18
(Cut-off ≤1:100)
N/Total (%)
Between-weeks’ difference *
1 10 to 10+6/7 15/96 (16.1%) 2/96 (2.2%) /
2 11 to 11+6/7 109/853 (12.8%) 17/853 (2.0%) Group 1 vs. Group 2 c
2=0.402, p = 0.52
3 12 to 12+6/7 158/1326 (11.9%) 15/1326 (1.1%) Group 2 vs. Group 3 c
2=0.313, p = 0.58
4 13 to 13+6/7 60/608 (9.9%) 10/608 (1.6%) Group 3 vs. Group 4 c
2=0.813, p = 0.37
* The differences are not significant (Data are referring to calculated Down syndrome biochemical risk)
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for PAPP-A measurement between 8-10 weeks’ gestation,
while its detection efficiency gradually decreased from 10
to 13 weeks’ gestation. On the other side, the discrimina-
tory power of free b-hCG was the best after the 12
th
week [26]. Our study hasn’tb e e nd e s i g n e dt op r o v et h e
best evidence, of neither of biochemical markers, in iden-
tifying the affected pregnancies. Small number of Down
syndrome cases in study population would not allow the
meaningful statistical analysis. The aim of this investiga-
tion was to discern a period in the first-trimester when
the biochemical markers are most specific and if FPR,
due to biochemistry, differ between the particular weeks.
In our pregnant women, the proportion of those at “high
biochemical risk” decreased from the week 10+0 to week
13+6, although the differences were not statistically sig-
nificant. This study was unfortunately underpowered to
detect such difference as significant. Over 1,000 pregnant
women per week are needed to detect the observed dif-
ference as significant, with the power of 0.8.
We think that it is important to get better insight in
possible physiological variations of the first-trimester bio-
chemical markers in particular weeks and to study the
degree of the oscillations of mean marker values between
the constant ranges of respective standard deviations.
Although the number of our pregnant women was not
large enough to form representative sub-groups, we have
clearly shown that the observed variations are not caused
by inaccuracy of analytical procedures or by a bias pro-
duced by inappropriate median values of biochemical
markers across the gestational range. Considering the
prevailing standards for analytical laboratories, this is of
value for correct interpretation of the results of biochem-
ical markers, particularly concerning their specificity.
Conclusions
We have shown the gestation related variations of log10
MoM values for biochemical markers, across the first-
trimester weeks in unaffected pregnancies. According to
our results, it seems unlikely that the observed varia-
tions could be attributed either to inaccuracy of analyti-
cal procedures or to inappropriately settled curves of
median values for the first-trimester biochemical mar-
kers. Improvement of the screening strategy implies, on
one side, following the guidelines of the Fetal Medicine
Foundation and, on the other, a better setting of the
timing for the biochemical parameters, for it can contri-
bute to a higher specificity of the screening.
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